Novavax Inc. shares plummeted in the extended session Thursday after the vaccine company said one of its lung infection vaccines did not meet endpoints in a late-stage clinical trial. Novavax shares plunged 84% to $1.30 on volume of more than 16 million shares. The company said its study in older adults for a vaccine against respiratory syncytial virus, which can cause bronchitis and pneumonia, did not meet primary or secondary clinical trial goals.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News